These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38498795)

  • 1. A Series of Articles About T Cells and Vaccines.
    Russell RS
    Viral Immunol; 2024 Mar; 37(2):59-60. PubMed ID: 38498795
    [No Abstract]   [Full Text] [Related]  

  • 2. Spatiotemporal behavior of T cells in vaccination.
    Chiodetti AL; Gérard A
    Int J Biochem Cell Biol; 2022 Jun; 147():106224. PubMed ID: 35537670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine.
    Tran CA; Lynch KT; Meneveau MO; Katyal P; Olson WC; Slingluff CL
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of T-cell response to COVID-19 vaccination in patients with multiple sclerosis treated by anti-CD20 therapies: New vaccines are required to be developed.
    Naser Moghadasi A
    Mult Scler Relat Disord; 2021 Nov; 56():103263. PubMed ID: 34543859
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue T cells in prophylactic and therapeutic vaccination responses.
    Maini MK
    Semin Arthritis Rheum; 2023 Dec; 63():152287. PubMed ID: 37925792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
    Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-7: A promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines?
    Zhao Y; Wei K; Chi H; Xia Z; Li X
    Front Immunol; 2022; 13():1022808. PubMed ID: 36389666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines for multiple sclerosis: progress to date.
    Correale J; Farez M; Gilmore W
    CNS Drugs; 2008; 22(3):175-98. PubMed ID: 18278975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model.
    Dhakal S; Loube J; Misplon JA; Lo CY; Creisher PS; Mulka KR; Deshpande S; Mitzner W; Klein SL; Epstein SL
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33627390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against murine coxsackievirus B3 myocarditis by T cell vaccination.
    Kishimoto C; Takada H; Hiraoka Y; Shinohara H; Kitazawa M
    J Mol Cell Cardiol; 2000 Dec; 32(12):2269-77. PubMed ID: 11113002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of T-cell immune response induced by two acellular pertussis vaccines in children five years after primary vaccination.
    Palazzo R; Carollo M; Bianco M; Fedele G; Schiavoni I; Pandolfi E; Villani A; Tozzi AE; Mascart F; Ausiello CM
    New Microbiol; 2016 Jan; 39(1):35-47. PubMed ID: 26922984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing effective vaccines: Cues from natural infection.
    Bhurani V; Mohankrishnan A; Morrot A; Dalai SK
    Int Rev Immunol; 2018; 37(5):249-265. PubMed ID: 29927676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell vaccination in humans.
    Kingsley GH; Verwilghen J
    Clin Exp Rheumatol; 1993; 11 Suppl 8():S63-4. PubMed ID: 8324954
    [No Abstract]   [Full Text] [Related]  

  • 17. Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines.
    Schweighoffer T; Schmidt W; Buschle M; Birnstiel ML
    Gene Ther; 1996 Sep; 3(9):819-24. PubMed ID: 8875231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination.
    Salgado Del Riego E; Saiz ML; Corte-Iglesias V; Leoz Gordillo B; Martin-Martin C; Rodríguez-Pérez M; Escudero D; Lopez-Larrea C; Suarez-Alvarez B
    Front Immunol; 2022; 13():942192. PubMed ID: 36275696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
    Yang A; Farmer E; Lin J; Wu TC; Hung CF
    Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunological basics of vaccination].
    Dalpke AH
    Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S61-4. PubMed ID: 19353473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.